Q-omics provides the consensus-scored RAB3GAP1 profile across patient tissues and cancer cell-line models. RAB3GAP1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB3GAP1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RAB3GAP1 RNA expression shows 21,392 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where RAB3GAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB3GAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB3GAP1 survival associations across molecular data types. RAB3GAP1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB3GAP1 RNA expression–survival associations across cancer types. High RAB3GAP1 expression shows unfavorable associations in ACC, UCEC, HNSC and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB3GAP1 RNA expression.
This table summarizes RAB3GAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RAB3GAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB3GAP1 shows lower tumor expression in KICH and UCEC and higher tumor expression in HNSC, LIHC, KIRP and CHOL. The HNSC box plot shows higher RAB3GAP1 RNA expression in tumor versus normal tissue (log2 FC = +0.736, t-test p < 0.001).
This table shows molecular features associated with RAB3GAP1 in patient tissues and cancer cell lines. In patient samples, RAB3GAP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB3GAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
